Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

9 Sep 2011 11:00

RNS Number : 9516N
Genus PLC
09 September 2011
 

9 September 2011

 

 

GENUS plc

('Genus' or 'the Company')

 

Directors' and PDMRs' Share Options

 

Genus announces that conditional nil-cost share options were granted under the Genus 2004 Performance Share Plan ("the Plan") today to:

 

·; Karim Bitar, Director (and new Chief Executive Officer with effect from 30 September 2011), as to 63,917 ordinary shares of 10 pence each in the Company ("Shares")

 

·; John Worby, Group Finance Director, as to 30,680 Shares

 

·;  Ian Biggs, Head of Global Product & Business Strategy, as to 20,453 Shares

 

·; Thomas Philip Acton, Chief Operating Officer, Europe & The Far East as to 20,453 Shares

 

·; Bill Christianson, Chief Operating Officer, The Americas, as to 20,453 Shares 

 

·; Ian Farrelly, Group Company Secretary & General Counsel as to 17,385 Shares, and

 

·; David Crosby, Group Financial Controller, as to 14,982 Shares.

 

Under the Plan these share options are subject to challenging performance conditions that relate to the growth in the Company's adjusted earnings per share over a three year performance period and which trigger vesting on an incremental basis.

 

The Company also announces that it today granted Karim Bitar a conditional share award ("Award") as to 77,259 Shares. Subject to the continued employment of Karim Bitar by the Company at the relevant vesting date, 36,685 Shares subject to the Award will vest on 31 January 2012 and 40,574 Shares subject to the Award will vest on 31 January 2013. No consideration is payable on the grant or vesting of the Award.

 

Karim Bitar has no direct shareholding in the Company and is the beneficial owner of 63,917 nil-cost share options and 77,259 conditional Shares. 

 

John Worby's direct shareholding stands at 10,000 Shares representing 0.017% of the issued share capital of the Company. In addition, he is the beneficial owner of 196,900 nil-cost share options. 

 

Ian Biggs' direct shareholding stands at 3,375 Shares representing 0.006% of the issued share capital of the Company. In addition, he is the beneficial owner of 129,983 nil-cost share options. 

 

Thomas Philip Acton's direct shareholding stands at 21,104 Shares representing 0.035% of the issued share capital of the Company. In addition, he is the beneficial owner of 123,537 nil-cost share options.

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 nil-cost share options and 26,189 market value share options.

 

Ian Farrelly has no direct shareholding in the Company and is the beneficial owner of 92,403 nil-cost share options.

 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 nil-cost share options and 16,373 market value share options. 

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUKOWRARAKRRR
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.